Literature DB >> 12683244

Infectious disease: changing antibiotic susceptibility.

Regis P Kowalski1, Lisa M Karenchak, Eric G Romanowski.   

Abstract

The field of ophthalmology is fortunate to have an array of antibiotics to treat bacterial infections. Because many of the older antibiotics are no longer useful for treating systemic infections, their use and associated acquired resistance have been reduced. These antibiotics, therefore, likely will continue to be effective for treating ophthalmic infections. The bacteria that cause recurrent infections (e.g., blepharitis) may acquire antibiotic resistance because of the repeated use of one particular agent for therapy (e.g., erythromycin). Recurrent pathologies and those that are treated with antibiotics that have varied broadspectrum activities should be cultured routinely to confirm infection and to institute appropriate therapy. Resistant trends of Staphylococcus aureus to the second-generation fluoroquinolones have been confirmed, and new trends of resistance for Pseudomonas aeruginosa have emerged. These antibiotics are effective but should be used judiciously to avoid bacterial resistance to them and to ensure their future potency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12683244     DOI: 10.1016/s0896-1549(02)00061-5

Source DB:  PubMed          Journal:  Ophthalmol Clin North Am        ISSN: 0896-1549


  14 in total

1.  [Bibrocathol eye ointment is efficacious in blepharitis. Results from a randomized, double-blind, controlled clinical trial].

Authors:  W Behrens-Baumann; C Niederdellmann; A Jehkul; R Kohnen
Journal:  Ophthalmologe       Date:  2006-11       Impact factor: 1.059

Review 2.  A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs.

Authors:  Y Jerold Gordon; Eric G Romanowski; Alison M McDermott
Journal:  Curr Eye Res       Date:  2005-07       Impact factor: 2.424

3.  Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis).

Authors:  Preston Howard Blomquist
Journal:  Trans Am Ophthalmol Soc       Date:  2006

4.  Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids.

Authors:  Sudharshan Hariharan; Sriram Gunda; Gyan P Mishra; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

5.  Microbiological profile of bacterial conjunctivitis in ibadan, Nigeria.

Authors:  A O Okesola; A O Salako
Journal:  Ann Ib Postgrad Med       Date:  2010-06

6.  In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.

Authors:  Regis P Kowalski; Tyler A Kowalski; Robert M Q Shanks; Eric G Romanowski; Lisa M Karenchak; Francis S Mah
Journal:  Cornea       Date:  2013-06       Impact factor: 2.651

7.  Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis.

Authors:  Lorenzo J Cervantes; Francis S Mah
Journal:  Clin Ophthalmol       Date:  2011-04-18

8.  Etiology and epidemiological analysis of glaucoma-filtering bleb infections in a tertiary eye care hospital in South India.

Authors:  R Ramakrishnan; M Jayahar Bharathi; Devendra Maheshwari; P M T Mohideen; Mona Khurana; C Shivakumar
Journal:  Indian J Ophthalmol       Date:  2011 Nov-Dec       Impact factor: 1.848

9.  Drug utilization study in ophthalmology outpatients at a tertiary care teaching hospital.

Authors:  Pradeep R Jadhav; Vijay V Moghe; Yeshwant A Deshmukh
Journal:  ISRN Pharmacol       Date:  2013-12-22

10.  External ocular surface bacterial isolates and their antimicrobial susceptibility patterns among pre-operative cataract patients at Mulago National Hospital in Kampala, Uganda.

Authors:  Barnabas Mshangila; Musana Paddy; Henry Kajumbula; Charles Ateenyi-Agaba; Binta Kahwa; Jeremiah Seni
Journal:  BMC Ophthalmol       Date:  2013-11-15       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.